Exhibit 99.1



CONTACT: GenoMed Inc.
David W. Moskowitz, MD, MA, FACP
(314) 983-9933
dwmoskowitz@genomedics.com
FOR IMMEDIATE RELEASE

ST. LOUIS,  MO.  -March 31, 2005 - GenoMed,  Inc.  (Pink Sheets:  GMED) has been
advised that one or more Internet  websites are recommending the purchase of the
Company's  stock,  and that  unsolicited  electronic  mail  has been  circulated
encouraging the purchase of the Company's  stock. The Company is not responsible
for,  and is  unaware  of the source of,  such  Internet  activity  and makes no
comment about the accuracy of such communications. The Company's management does
not comment on research reports or rumors concerning the Company's activities or
stock price.

Safe Harbor Statement

This press  release may contain  forward  looking  statements,  including  those
statements pertaining to GenoMed,  Inc.'s finances and treatments.  The words or
phrases  "ought  to,"  "should,"  "could,"  "may," or  similar  expressions  are
intended  to  identify  "forward-looking  statements"  within the meaning of the
Private  Securities  Litigation  Reform Act of 1995. Actual results could differ
materially from those projected in the forward looking statements as a result of
a number of risks and  uncertainties,  including but not limited to: (a) whether
our treatment for West Nile virus  encephalitis will continue to be as effective
as it has been so far in humans;  (b) whether our server  holds up to  increased
demand;  (c) our  research  and  development  being  subject to other  economic,
regulatory,  governmental, and technological factors. Statements made herein are
as of the date of this press  release  and  should not be relied  upon as of any
subsequent date.  Unless  otherwise  required by applicable law, we specifically
disclaim any  obligation  to update any  forward-looking  statements  to reflect
occurrences, developments,  unanticipated events or circumstances after the date
of such statement.